PCLO2

PharmaCielo Holdings earns a Neutral rating with 3/5 conviction, based on a 36.5 composite score. Regulatory is the strongest pillar at 50.0, supported by a 55.0 jurisdiction score and an 80.0 enforcement subscore. Market contributes 40.0, although institutional pricing feeds provide no available quote, limiting evidence of price discovery and trading support. Editorial contributes 30.0, reflecting no newsroom or brief activity in CIN newsroom coverage. Fundamentals rank last at 27.0, with weak growth, negative profitability measures, a low market-cap tier, and only partial support from the cash-runway subscore. The pillar mix places PCLO2 squarely in the Neutral band rather than supporting a more constructive stance.

Licensed fundamentals data show year-over-year revenue contraction of approximately 46%, paired with a gross margin near negative 18%. The reported operating-margin metric exceeds 260%, but that isolated subscore does not offset an EBITDA loss of roughly $2.6 million and a net loss of about $4.7 million. The cash-burn ratio stands near 0.31, while the cash-runway subscore is 36.1, consistent with the stated stretched financial condition. Primary regulatory filings show no dated latest filing, producing a cadence subscore of 25.0. No regulatory events were recorded across either the 90-day or 180-day period, and no enforcement hits were identified. That clean enforcement record supports the strongest regulatory subcomponent, but sparse filing cadence constrains the overall regulatory contribution.

The clearest forward catalyst sits within the regulatory pillar. A new primary regulatory filing with current operating and financial disclosure would directly address the weakest element inside the company’s highest-scoring pillar, improve visibility into reporting continuity, and provide a firmer basis for assessing whether the severe revenue decline, negative gross margin, EBITDA loss, and net loss are stabilizing. Continued absence of enforcement hits preserves the existing regulatory foundation, while a sustained filing rhythm would deliver the most credible route toward a higher composite assessment. The single most important signal to watch is the appearance of a current primary regulatory filing that establishes a consistent reporting cadence.